US8183344B2
(en)
*
|
1996-04-24 |
2012-05-22 |
University Of Michigan |
Inactivation resistant factor VIII
|
US7173003B2
(en)
|
2001-10-10 |
2007-02-06 |
Neose Technologies, Inc. |
Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
|
US7214660B2
(en)
|
2001-10-10 |
2007-05-08 |
Neose Technologies, Inc. |
Erythropoietin: remodeling and glycoconjugation of erythropoietin
|
AU2004236174B2
(en)
|
2001-10-10 |
2011-06-02 |
Novo Nordisk A/S |
Glycopegylation methods and proteins/peptides produced by the methods
|
WO2006127896A2
(en)
|
2005-05-25 |
2006-11-30 |
Neose Technologies, Inc. |
Glycopegylated factor ix
|
US8791070B2
(en)
|
2003-04-09 |
2014-07-29 |
Novo Nordisk A/S |
Glycopegylated factor IX
|
TWI353991B
(en)
|
2003-05-06 |
2011-12-11 |
Syntonix Pharmaceuticals Inc |
Immunoglobulin chimeric monomer-dimer hybrids
|
US9005625B2
(en)
|
2003-07-25 |
2015-04-14 |
Novo Nordisk A/S |
Antibody toxin conjugates
|
US8633157B2
(en)
|
2003-11-24 |
2014-01-21 |
Novo Nordisk A/S |
Glycopegylated erythropoietin
|
US20080305992A1
(en)
|
2003-11-24 |
2008-12-11 |
Neose Technologies, Inc. |
Glycopegylated erythropoietin
|
EP1699469B1
(en)
*
|
2003-12-03 |
2010-04-07 |
University of Rochester |
Recombinant factor viii having increased specific activity
|
US20060040856A1
(en)
|
2003-12-03 |
2006-02-23 |
Neose Technologies, Inc. |
Glycopegylated factor IX
|
CN101072789B
(zh)
|
2004-01-08 |
2013-05-15 |
生物种属学股份公司 |
肽的o-连接的糖基化
|
US20080300173A1
(en)
|
2004-07-13 |
2008-12-04 |
Defrees Shawn |
Branched Peg Remodeling and Glycosylation of Glucagon-Like Peptides-1 [Glp-1]
|
SI2586456T1
(sl)
|
2004-10-29 |
2016-05-31 |
Ratiopharm Gmbh |
Preoblikovanje in glikopegliacija fibroblastnega rastnega faktorja (FGF)
|
NZ556436A
(en)
|
2005-01-10 |
2010-11-26 |
Biogenerix Ag |
Glycopegylated granulocyte colony stimulating factor
|
US9187546B2
(en)
|
2005-04-08 |
2015-11-17 |
Novo Nordisk A/S |
Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
|
WO2006108590A1
(en)
*
|
2005-04-14 |
2006-10-19 |
Csl Behring Gmbh |
Modified coagulation factor viii with enhanced stability and its derivates
|
US20070105755A1
(en)
|
2005-10-26 |
2007-05-10 |
Neose Technologies, Inc. |
One pot desialylation and glycopegylation of therapeutic peptides
|
WO2007056191A2
(en)
|
2005-11-03 |
2007-05-18 |
Neose Technologies, Inc. |
Nucleotide sugar purification using membranes
|
CA2632714A1
(en)
|
2005-12-07 |
2007-06-14 |
Technische Universitaet Muenchen |
Small peptidic and peptido-mimetic affinity ligands for factor viii and factor viii-like proteins
|
WO2008005847A2
(en)
*
|
2006-06-30 |
2008-01-10 |
The Regents Of The University Of Michigan |
Method of producing factor viii proteins by recombinant methods
|
US20090203077A1
(en)
*
|
2006-06-30 |
2009-08-13 |
The Regents Of The University Of Michigan |
Method of producing factor viii proteins by recombinant methods
|
US20080274958A1
(en)
|
2006-07-21 |
2008-11-06 |
Neose Technologies, Inc. |
Glycosylation of peptides via o-linked glycosylation sequences
|
JP2010505874A
(ja)
|
2006-10-03 |
2010-02-25 |
ノヴォ ノルディスク アー/エス |
ポリペプチドコンジュゲートの精製方法
|
CN101646779B
(zh)
*
|
2007-02-23 |
2014-12-03 |
Sk化学株式会社 |
制备和纯化因子viii及其衍生物的方法
|
RS52845B
(en)
|
2007-04-03 |
2013-12-31 |
Biogenerix Ag |
Methods of treatment using glycopegylated g-csf
|
US9493499B2
(en)
|
2007-06-12 |
2016-11-15 |
Novo Nordisk A/S |
Process for the production of purified cytidinemonophosphate-sialic acid-polyalkylene oxide (CMP-SA-PEG) as modified nucleotide sugars via anion exchange chromatography
|
KR20100113478A
(ko)
*
|
2007-11-01 |
2010-10-21 |
유니버시티 오브 로체스터 |
증가된 안정성을 갖는 재조합 인자 ⅴⅰⅰⅰ
|
CA2711503A1
(en)
*
|
2008-01-08 |
2009-07-16 |
Biogenerix Ag |
Glycoconjugation of polypeptides using oligosaccharyltransferases
|
EP2626079A3
(en)
|
2008-02-27 |
2014-03-05 |
Novo Nordisk A/S |
Conjungated factor VIII molecules
|
CA2724630A1
(en)
*
|
2008-05-16 |
2009-11-19 |
Bayer Healthcare Llc |
Targeted coagulation factors and method of using the same
|
NZ628987A
(en)
|
2009-02-03 |
2015-11-27 |
Amunix Operating Inc |
Extended recombinant polypeptides and compositions comprising same
|
US9062299B2
(en)
|
2009-08-24 |
2015-06-23 |
Amunix Operating Inc. |
Coagulation factor IX compositions and methods of making and using same
|
AU2010300292B2
(en)
|
2009-10-02 |
2016-11-10 |
The Children's Hospital Of Philadelphia |
Compositions and methods for enhancing coagulation factor VIII function
|
EA038618B1
(ru)
|
2009-12-06 |
2021-09-23 |
Биовератив Терапьютикс Инк. |
Химерные и гибридные полипептиды фактора viii-fc и способы их применения
|
HUE044419T2
(hu)
|
2010-07-09 |
2019-10-28 |
Bioverativ Therapeutics Inc |
Feldogozható egyetlen láncú molekulák és ezek alkalmazásával készült peptidek
|
US9611310B2
(en)
|
2010-07-09 |
2017-04-04 |
Bioverativ Therapeutics Inc. |
Systems for factor VIII processing and methods thereof
|
MX347503B
(es)
*
|
2010-11-05 |
2017-04-26 |
Baxalta Inc |
Una variante nueva del factor viii antihemofílico que tiene actividad específica incrementada.
|
PT2717898T
(pt)
|
2011-06-10 |
2019-05-20 |
Bioverativ Therapeutics Inc |
Compostos pró-coagulantes e processos para a sua utilização
|
RS58578B1
(sr)
|
2011-07-08 |
2019-05-31 |
Bioverativ Therapeutics Inc |
Faktor viii himernih i hibridnih polipeptida i postupci za njihovu upotrebu
|
EP2737311B1
(en)
|
2011-07-25 |
2020-12-02 |
Bioverativ Therapeutics Inc. |
Assays to monitor bleeding disorders
|
ES2600081T3
(es)
|
2011-10-18 |
2017-02-07 |
Csl Behring Gmbh |
Uso de glucosaminoglicanos sulfatados para mejorar la biodisponibilidad del Factor VIII
|
US9511123B2
(en)
|
2011-10-18 |
2016-12-06 |
Csl Behring Gmbh |
Combined use of a sulfated glycosaminoglycan and a hyaluronidase for improving the bioavailability of factor VIII
|
CA2850579A1
(en)
*
|
2011-10-18 |
2013-04-25 |
Carsten Horn |
Method for improving the stability of purified factor viii after reconstitution
|
CN109111526A
(zh)
|
2012-01-12 |
2019-01-01 |
比奥贝拉蒂治疗公司 |
嵌合因子viii多肽及其用途
|
DK2802668T3
(en)
|
2012-01-12 |
2018-11-19 |
Bioverativ Therapeutics Inc |
METHODS FOR REDUCING IMMUNOGENICITY AGAINST FACT VIII OF INDIVIDUALS THAT UNDERSTAND FACT VIII THERAPY
|
US10370430B2
(en)
|
2012-02-15 |
2019-08-06 |
Bioverativ Therapeutics Inc. |
Recombinant factor VIII proteins
|
SG10201606783RA
(en)
|
2012-02-15 |
2016-10-28 |
Amunix Operating Inc |
Factor viii compositions and methods of making and using same
|
CN104519897A
(zh)
|
2012-06-08 |
2015-04-15 |
比奥根艾迪克Ma公司 |
促凝血化合物
|
JP2015525222A
(ja)
|
2012-06-08 |
2015-09-03 |
バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. |
キメラ性凝固因子
|
WO2014008480A2
(en)
|
2012-07-06 |
2014-01-09 |
Biogen Idec Ma Inc. |
Cell line expressing single chain factor viii polypeptides and uses thereof
|
KR101395736B1
(ko)
*
|
2012-07-10 |
2014-05-16 |
아주대학교산학협력단 |
인간 혈액응고인자 ⅷ 도메인 특이적 항체 및 이의 제조방법
|
PL2882450T3
(pl)
|
2012-07-11 |
2020-06-29 |
Bioverativ Therapeutics Inc. |
Kompleks czynnika viii z xten i białkiem czynnika von willebranda oraz jego zastosowania
|
HK1212882A1
(zh)
|
2012-07-25 |
2016-06-24 |
Bioverativ Therapeutics Inc. |
血液因子的監測分析及其用途
|
US10391152B2
(en)
|
2012-10-18 |
2019-08-27 |
Bioverativ Therapeutics Inc. |
Methods of using a fixed dose of a clotting factor
|
EP2914293A4
(en)
|
2012-10-30 |
2016-04-20 |
Biogen Ma Inc |
METHOD OF USE OF FVIII POLYPEPTIDE
|
FI2956477T4
(fi)
*
|
2013-02-15 |
2024-04-24 |
Bioverativ Therapeutics Inc |
Optimoitu tekijä viii:n geeni
|
TWI683666B
(zh)
|
2013-03-15 |
2020-02-01 |
美商百歐維拉提夫治療公司 |
因子ix多肽調配物
|
RS60003B1
(sr)
|
2013-03-15 |
2020-04-30 |
Bioverativ Therapeutics Inc |
Formulacije polipeptida faktora viii
|
EP2796145B1
(en)
|
2013-04-22 |
2017-11-01 |
CSL Ltd. |
A covalent complex of von willebrand factor and faktor viii linked by a disulphide bridge
|
CN105392495A
(zh)
|
2013-06-28 |
2016-03-09 |
比奥根Ma公司 |
具有xten的凝血酶可裂解连接子和其用途
|
EP3043813B1
(en)
|
2013-08-08 |
2021-01-13 |
Bioverativ Therapeutics Inc. |
Purification of chimeric fviii molecules
|
US10548953B2
(en)
|
2013-08-14 |
2020-02-04 |
Bioverativ Therapeutics Inc. |
Factor VIII-XTEN fusions and uses thereof
|
WO2015070014A1
(en)
|
2013-11-08 |
2015-05-14 |
Biogen Idec Ma Inc. |
Procoagulant fusion compound
|
WO2015085276A1
(en)
|
2013-12-06 |
2015-06-11 |
Biogen Idec Ma Inc. |
Population pharmacokinetics tools and uses thereof
|
RS63583B1
(sr)
|
2014-01-10 |
2022-10-31 |
Bioverativ Therapeutics Inc |
Himerni proteini faktora viii i njihova upotreba
|
US10822393B2
(en)
*
|
2014-01-20 |
2020-11-03 |
Octapharma Ag |
Process for manufacturing factor VIII having an improved ratio of FVIII:C/FVIII/AG
|
KR20230136616A
(ko)
|
2014-02-04 |
2023-09-26 |
바이오젠 엠에이 인코포레이티드 |
번역 후 변형을 강화시키기 위한 통류 방식 양이온교환 크로마토그래피의 용도
|
WO2016004113A1
(en)
|
2014-06-30 |
2016-01-07 |
Biogen Ma Inc. |
Optimized factor ix gene
|
PL3177317T3
(pl)
|
2014-08-04 |
2020-07-27 |
Csl Limited |
Formulacja czynnika viii
|
MA40864A
(fr)
|
2014-10-31 |
2017-09-05 |
Biogen Ma Inc |
Hypotaurine, gaba, bêta-alanine et choline pour la régulation de l'accumulation de sous-produits résiduaires dans des procédés de culture de cellules mammifères
|
BR112017018468A2
(pt)
|
2015-03-06 |
2018-04-17 |
Csl Behring Recombinant Facility Ag |
fator de von willebrand modificado com meia-vida aumentada
|
BR112017023785A2
(pt)
|
2015-05-22 |
2018-07-17 |
Csl Behring Recombinant Facility Ag |
polipeptídeos do fator de von willebrand truncados para tratar hemofilia
|
EP4089109A3
(en)
|
2015-05-22 |
2023-03-01 |
CSL Behring Lengnau AG |
Methods for preparing modified von willebrand factor
|
EP3331608A4
(en)
|
2015-08-03 |
2019-05-01 |
Bioverativ Therapeutics Inc. |
FACTOR IX FUSION PROTEINS AND METHOD FOR THE PRODUCTION AND USE THEREOF
|
WO2017050820A1
(en)
*
|
2015-09-22 |
2017-03-30 |
Novo Nordisk A/S |
Fviii fusion proteins
|
EA038288B1
(ru)
|
2015-11-13 |
2021-08-05 |
Такеда Фармасьютикал Компани Лимитед |
Вирусные векторы, кодирующие рекомбинантные варианты fviii с повышенной экспрессией для генной терапии гемофилии a
|
AU2016354550B2
(en)
|
2015-11-13 |
2020-04-16 |
Takeda Pharmaceutical Company Limited |
Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a
|
ES2909573T3
(es)
|
2016-01-07 |
2022-05-09 |
CSL Behring Lengnau AG |
Factor de von Willebrand truncado mutado
|
CN109072214B
(zh)
|
2016-02-01 |
2023-02-17 |
比奥贝拉蒂治疗公司 |
优化的因子viii基因
|
WO2017222330A1
(ko)
|
2016-06-24 |
2017-12-28 |
재단법인 목암생명과학연구소 |
재조합 단쇄 fviii 및 그 화학 접합물
|
EP3476937A4
(en)
|
2016-06-24 |
2019-12-04 |
Mogam Institute for Biomedical Research |
CHIMERIC PROTEIN WITH FVIII AND VWF FACTORS AND USE THEREOF
|
JP6351679B2
(ja)
*
|
2016-09-30 |
2018-07-04 |
エスケー ケミカルズ カンパニー リミテッド |
第viii因子とその誘導体の製造及び精製方法
|
CN110381986B
(zh)
|
2016-11-11 |
2023-08-18 |
康诺贝林伦瑙有限公司 |
用于血管外施予以治疗或预防凝血疾病的截短型冯维勒布兰德因子多肽
|
AU2017358861B2
(en)
|
2016-11-11 |
2022-02-17 |
CSL Behring Lengnau AG |
Truncated von Willebrand Factor polypeptides for treating hemophilia
|
MA46967A
(fr)
|
2016-12-02 |
2019-10-09 |
Bioverativ Therapeutics Inc |
Méthodes de traitement de l'arthropathie hémophilique à l'aide de facteurs de coagulation chimériques
|
MX2019006446A
(es)
|
2016-12-02 |
2019-12-11 |
Bioverativ Therapeutics Inc |
Métodos para inducir tolerancia inmunológica a factores de coagulación.
|
BR112019026743A2
(pt)
|
2017-06-22 |
2020-06-30 |
CSL Behring Lengnau AG |
modulação da imunogenicidade de fviii através de vwf truncado
|
MX2020001593A
(es)
|
2017-08-09 |
2020-07-13 |
Bioverativ Therapeutics Inc |
Moleculas de acido nucleico y usos de las mismas.
|
CN111295094A
(zh)
|
2017-10-09 |
2020-06-16 |
泰尔茂比司特生物技术有限公司 |
冻干容器及使用冻干容器的方法
|
EP3746136A1
(en)
|
2018-02-01 |
2020-12-09 |
Bioverativ Therapeutics Inc. |
Use of lentiviral vectors expressing factor viii
|
EP3773517A1
(en)
|
2018-04-04 |
2021-02-17 |
Sigilon Therapeutics, Inc. |
Implantable particles and related methods
|
SG11202010767SA
(en)
|
2018-05-18 |
2020-11-27 |
Bioverativ Therapeutics Inc |
Methods of treating hemophilia a
|
TW202006141A
(zh)
|
2018-07-16 |
2020-02-01 |
美商巴克斯歐塔公司 |
使用編碼具有增加表現的重組fviii變異體之病毒載體的a型血友病之基因療法
|
JP7602454B2
(ja)
|
2018-08-09 |
2024-12-18 |
バイオベラティブ セラピューティクス インコーポレイテッド |
核酸分子及び非ウイルス遺伝子治療のためのそれらの使用
|
US20220118063A1
(en)
*
|
2018-09-19 |
2022-04-21 |
Cell Machines, Inc. |
Methods and compositions related to improved factor viii long half-life coagulation complexes
|
UY38389A
(es)
|
2018-09-27 |
2020-04-30 |
Sigilon Therapeutics Inc |
Dispositivos implantables para terapia celular y métodos relacionados
|
TWI851647B
(zh)
|
2019-01-16 |
2024-08-11 |
日商武田藥品工業股份有限公司 |
用於a型血友病基因治療之編碼表現增加之重組fviii變異體的病毒載體
|
SG11202108357PA
(en)
|
2019-02-15 |
2021-08-30 |
Crispr Therapeutics Ag |
Gene editing for hemophilia a with improved factor viii expression
|
JP7471316B2
(ja)
|
2019-03-14 |
2024-04-19 |
テルモ ビーシーティー バイオテクノロジーズ,エルエルシー |
マルチパート凍結乾燥容器
|
EP3736286A1
(en)
|
2019-05-09 |
2020-11-11 |
Biotest AG |
Single chain factor viii molecule
|
JP7585217B2
(ja)
*
|
2019-06-05 |
2024-11-18 |
クリスパー セラピューティクス アクチェンゲゼルシャフト |
改善された第viii因子発現による血友病aのための遺伝子編集
|
US20220233650A1
(en)
|
2019-06-19 |
2022-07-28 |
Bioverativ Therapeutics Inc. |
Recombinant factor viii-fc for treating hemophilia and low bone mineral density
|
KR20220029733A
(ko)
|
2019-07-04 |
2022-03-08 |
체에스엘 베링 렝나우 아게 |
응고 인자 viii의 시험관내 안정성을 증가시키기 위한 절단된 폰 빌레브란트 인자 (vwf)
|
WO2021067389A1
(en)
|
2019-09-30 |
2021-04-08 |
Bioverativ Therapeutics Inc. |
Lentiviral vector formulations
|
EP4058049A1
(en)
|
2019-11-11 |
2022-09-21 |
CSL Behring Lengnau AG |
Polypeptides for inducing tolerance to factor viii
|
JP2023506171A
(ja)
|
2019-12-12 |
2023-02-15 |
武田薬品工業株式会社 |
発現が上昇した組換えfviiiバリアントをコードするウイルスベクターを使用する、血友病aの遺伝子療法
|
JP7681268B2
(ja)
*
|
2020-03-30 |
2025-05-22 |
シスメックス株式会社 |
血液凝固活性の測定方法
|
TW202208619A
(zh)
|
2020-06-24 |
2022-03-01 |
美商百歐維拉提夫治療公司 |
用於純化病毒載體之方法
|
EP4355768A1
(en)
|
2021-06-14 |
2024-04-24 |
Takeda Pharmaceutical Company Limited |
Gene therapy of hemophilia a using viral vectors encoding recombinant fviii variants with increased expression
|
CN117836319A
(zh)
|
2021-08-23 |
2024-04-05 |
比奥维拉迪维治疗股份有限公司 |
优化的因子viii基因
|
EP4408874A1
(en)
|
2021-09-30 |
2024-08-07 |
Bioverativ Therapeutics Inc. |
Nucleic acids encoding factor viii polypeptides with reduced immunogenicity
|
WO2024081309A1
(en)
|
2022-10-11 |
2024-04-18 |
Sigilon Therapeutics, Inc. |
Engineered cells and implantable elements for treatment of disease
|
WO2025008774A1
(en)
|
2023-07-05 |
2025-01-09 |
Takeda Pharmaceutical Company Limited |
Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a
|